BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 29, 2025
Home » Newsletters » BioWorld

BioWorld

Sep. 30, 2021

View Archived Issues

For $11.5B, Merck will acquire Acceleron

In the year’s second biggest M&A deal, Merck & Co. Inc. will take over pulmonary and hematologic specialist Acceleron Pharma Inc. for $11.5 billion. The acquisition brings Merck a pair of potential blockbuster drugs, one of them already marketed. There is sotatercept, in development for treating pulmonary hypertension (PH), and also Reblozyl (luspatercept-aamt), the first and only erythroid maturation agent approved in the U.S., Europe and Canada for treating anemia in certain blood disorders. Read More
CBMG’s facility in Shanghai

CBMG bags $120M in its first financing since going private, funds to benefit CAR T candidates

Cell therapy developer Cellular Biomedicine Group Inc. (CBMG) completed a $120 million series A financing, its first since becoming a private company. The funds will benefit the U.S. and China-based firm’s CAR T pipeline, and the round was jointly led by Astrazeneca-CICC Fund, Sequoia Capital China and Yunfeng Capital. Existing investors including GIC Private Ltd. (formerly Government of Singapore Investment Corp.) and TF Capital also took part. Read More
Cell research illustration

Opportunities, challenges as regenerative medicine explodes

As if it were needed, Amicus Therapeutics Inc.’s spin-off of its gene therapy work and PDUFA VII’s provisions to increase the capacity of the FDA’s Center for Biologics Evaluation and Research offered further proof this week of the global explosion that’s happening in the regenerative medicine field. Read More
Drug-vial-syringe

One visit, two jabs: Co-administration of flu, COVID-19 vaccines safe and effective, study shows

LONDON – It is both safe and effective for people to receive an influenza vaccine at the same time as a COVID-19 vaccine, with no negative impacts on the strength of the immune response produced by either vaccine and reported side effects mainly mild to moderate. Only nine of 679 participants in a U.K. study testing combinations of different flu and COVID-19 vaccines said they would not want to have two different vaccines at the same time in the future. Six of those were in the control arm of the trial, in which saline was injected as a placebo. Read More
Vial and syringe

Roche-Regeneron cocktail reduces viral load in hospitalized COVID-19 patients

New data on the COVID-19 antibody therapy Ronapreve (casirivimab + imdevimab), already used to treat non-hospitalized patients in multiple countries, could potentially support expanding its use to certain recently hospitalized patients with the disease. Read More

11th Circuit slaps FDA for violating orphan exclusivity

The FDA’s 2019 approval of Jacobus Pharmaceutical Co. Inc.’s Ruzurgi to treat children ages 6 to 17 with Lambert-Eaton myasthenic syndrome must be set aside because it violated the Orphan Drug Act in light of Catalyst Pharmaceuticals Inc.’s seven-year orphan exclusivity for its LEMS drug, Firdapse, the U.S. Court of Appeals for the 11th Circuit ruled Sept. 30. Read More

IFPMA partners with H3D-F to drive drug R&D in Africa

Despite shouldering a quarter of the global disease burden, Africa is responsible for only 2% of the world research on new infections. Aiming to bolster R&D in the region, the H3D-Foundation and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) launched a three-year partnership to strengthen capacity for health innovation in Africa. Read More

New EMA measures aimed at reducing use of animals in drug development

The EMA is taking another step in its efforts to reduce animal testing in drug development. Read More

Appointments and advancements for Sept. 30, 2021

New hires and promotions in the biopharma industry, including: Arch, Elios, Genenta, Hangzhou Chance, Hibercell, Immunicum, Immunos, Isarna, Medicenna, Merck, Mind Medicine, Nurix, Obseva, Pharmather, Synairgen, Targovax, XNK. Read More

Conference data for Sept. 30, 2021: EADV

New and updated preclinical and clinical data presented by biopharma firms at the European Academy of Dermatology and Venereology Congress, including: Abbvie, Arcutis, BMS, Dermavant, Eli Lilly, Leo, Novartis, Rapt, Sanofi. Read More

Conference data for Sept. 30, 2021: IDWeek

New and updated preclinical and clinical data presented by biopharma firms at IDWeek 2021, including: Allovir, Codagenix, Ferring, Humanigen, Iliad, Mycovia, Neoleukin, Peptilogics, Scynexis, Seqirus, Viiv. Read More

Financings for Sept. 30, 2021

Biopharmas raising money in public or private financings, including: Advent, Esobiotec, Micreos, Skye, Spero, Theseus, Trialspark, Ventyx. Read More

In the clinic for Sept. 30, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: ADC, Addex, Allena, Celldex, Editas, Epicentrx, Galderma, Glyscend, Grunenthal, Hanmi, Hepion, Innovent, Janssen, Longeveron, Neuronascent, Nrx, Pfizer, PTC, Solid, Synaffix, Syros, UCB, VBI, Wave Life. Read More

Other news to note for Sept. 30, 2021

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 1910 Genetics, APT, AIM Immunotech, Bioadvance, Biontech, Cantargia, Creative Manufacturing Properties, Cynata, Fujifilm, Gigagen, Grifols, GSK, Immunogenesis, Inflammasome, Inspirna JCR, Mab Discovery, Mannkind, Merck & Co., Merck KGaA, Otsuka, Proteonic, Race Oncology, Rgenix, Sirpant Immunotherapeutics Starton, Sutro, Sunovion, Sumitomo Dainippon, Takeda. Read More

Regulatory actions for Sept. 30, 2021

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: AB Science, Abbvie, Acacia, Alnylam, Amicus, Bridgebio, Catalyst, Eli Lilly, Everest, Helsinn, Pharmazz, Recursion, Taysha. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 27, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 27, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • BIO2025: John Crowley and Martin Makary

    BIO 2025: Makary lays out FDA’s path, launches pilot review program

    BioWorld
    On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...
  • Andembry

    New orphan drug, CSL’s garadacimab, cleared for hereditary angioedema

    BioWorld
    Following a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing